Washington Trust Company Has Cut Its Estee Lauder Cos Inc/The (EL) Stake; Amedisys (AMED)’s Sentiment Is 1.86

The Estée Lauder Companies Inc. (NYSE:EL) Logo

Washington Trust Company decreased Estee Lauder Cos Inc/The (EL) stake by 2.44% reported in 2018Q4 SEC filing. Washington Trust Company sold 4,546 shares as Estee Lauder Cos Inc/The (EL)’s stock rose 11.48%. The Washington Trust Company holds 181,689 shares with $23.64 million value, down from 186,235 last quarter. Estee Lauder Cos Inc/The now has $58.80B valuation. The stock increased 1.76% or $2.81 during the last trading session, reaching $162.8. About 1.08M shares traded. The Estée Lauder Companies Inc. (NYSE:EL) has risen 12.81% since March 15, 2018 and is uptrending. It has outperformed by 8.44% the S&P500. Some Historical EL News: 06/03/2018 The Estée Lauder Companies Presentation at the Bank of America Merrill Lynch 2018 Consumer & Retail Technology Conference; 08/03/2018 – Detailed Research: Economic Perspectives on Noble Energy, Molson Coors Brewing, Booz Allen Hamilton Holding, Estee Lauder Compa; 15/05/2018 – POINT72 SINGAPORE BOOSTED EL IN 1Q: 13F; 02/05/2018 – ESTEE LAUDER: TESTING ISSUES WON’T AFFECT NEW PRODUCT LAUNCHES; 02/05/2018 – Estee Lauder Product Testing Issue Clouds Quarterly Sales Gains; 02/05/2018 – Estee Lauder 3Q Net $372M; 25/04/2018 – Estee Lauder to Expand Paid Parental Leave Policy to 20 Weeks Effective May; 21/05/2018 – Estee Lauder Rises for 10 Days; Tied for Longest Rally; 13/03/2018 – ESTEE LAUDER COMPANIES INC EL.N : CREDIT SUISSE INITIATES WITH OUTPERFORM, $162 TARGET PRICE; 23/04/2018 – The Estée Lauder Companies to Webcast Discussion of Fiscal 2018 Third Quarter Financial Results on May 2, 2018

Amedisys Inc (AMED) investors sentiment increased to 1.86 in Q4 2018. It’s up 0.11, from 1.75 in 2018Q3. The ratio increased, as 158 institutional investors opened new and increased positions, while 85 sold and reduced stakes in Amedisys Inc. The institutional investors in our database reported: 29.48 million shares, up from 28.91 million shares in 2018Q3. Also, the number of institutional investors holding Amedisys Inc in top ten positions was flat from 1 to 1 for the same number . Sold All: 20 Reduced: 65 Increased: 97 New Position: 61.

Investors sentiment increased to 1.04 in Q4 2018. Its up 0.25, from 0.79 in 2018Q3. It increased, as 45 investors sold EL shares while 232 reduced holdings. 67 funds opened positions while 220 raised stakes. 188.10 million shares or 0.38% more from 187.38 million shares in 2018Q3 were reported. Delta Asset Management Ltd Tn, a Tennessee-based fund reported 400 shares. Acadian Asset Management Limited Company has invested 1.19% in The Est̩e Lauder Companies Inc. (NYSE:EL). Epoch Ptnrs Inc reported 0.02% in The Est̩e Lauder Companies Inc. (NYSE:EL). Ashfield Cap Prtnrs Ltd Company, a California-based fund reported 35,735 shares. Manitoba РCanada-based Great West Life Assurance Can has invested 0.08% in The Est̩e Lauder Companies Inc. (NYSE:EL). Liberty Capital Inc holds 3,643 shares. Moreover, Bollard Gru Limited Company has 0% invested in The Est̩e Lauder Companies Inc. (NYSE:EL). Grantham Mayo Van Otterloo & Limited Liability Company owns 140,347 shares. Captrust Advisors has 0.01% invested in The Est̩e Lauder Companies Inc. (NYSE:EL). Arrowstreet Cap Partnership reported 1.10 million shares. 14,222 are owned by Fruth Inv Mngmt. Baillie Gifford Co holds 0.03% or 188,260 shares. The New York-based Brown Brothers Harriman And has invested 0% in The Est̩e Lauder Companies Inc. (NYSE:EL). Magnetar Ltd accumulated 4,027 shares or 0.01% of the stock. Walleye Trading has 19,197 shares.

Since October 31, 2018, it had 0 buys, and 23 selling transactions for $160.05 million activity. 54,303 The Estée Lauder Companies Inc. (NYSE:EL) shares with value of $7.14M were sold by Demsey John. Another trade for 29,366 shares valued at $4.36M was made by Hertzmark Hudis Jane on Wednesday, February 6. Another trade for 38,080 shares valued at $5.84M was made by LAUDER RONALD S FOUNDATION on Monday, February 11. $4.12 million worth of The Estée Lauder Companies Inc. (NYSE:EL) shares were sold by O’HARE MICHAEL. $2.03M worth of stock was sold by TRAVIS TRACEY THOMAS on Monday, December 3. 13,759 The Estée Lauder Companies Inc. (NYSE:EL) shares with value of $2.10M were sold by FRIBOURG PAUL J. Another trade for 8,187 shares valued at $1.26 million was made by PARSONS RICHARD D on Tuesday, February 12.

Among 11 analysts covering The Estee Lauder Cos (NYSE:EL), 7 have Buy rating, 1 Sell and 3 Hold. Therefore 64% are positive. The Estee Lauder Cos had 15 analyst reports since September 20, 2018 according to SRatingsIntel. The firm earned “Hold” rating on Wednesday, February 6 by Berenberg. The rating was maintained by Credit Suisse with “Outperform” on Thursday, November 1. The stock has “Market Perform” rating by Wells Fargo on Thursday, January 10. The stock of The Estée Lauder Companies Inc. (NYSE:EL) earned “Outperform” rating by Wells Fargo on Wednesday, October 17. The firm has “Neutral” rating by JP Morgan given on Friday, October 12. The company was maintained on Thursday, March 7 by RBC Capital Markets. BMO Capital Markets maintained The Estée Lauder Companies Inc. (NYSE:EL) rating on Wednesday, February 6. BMO Capital Markets has “Market Perform” rating and $155 target. DA Davidson maintained the stock with “Buy” rating in Thursday, March 7 report. Raymond James maintained the shares of EL in report on Thursday, November 1 with “Outperform” rating. Wells Fargo maintained The Estée Lauder Companies Inc. (NYSE:EL) rating on Wednesday, March 6. Wells Fargo has “Hold” rating and $142 target.

More notable recent The Estée Lauder Companies Inc. (NYSE:EL) news were published by: Benzinga.com which released: “Analysts: Estée Lauder’s Strength Isn’t Just Cosmetic (NYSE:EL) – Benzinga” on March 07, 2019, also Benzinga.com with their article: “Mile High Labs International Launches On-Farm Hemp Processing Solution – Benzinga” published on March 15, 2019, Forbes.com published: “What Are Estee Lauder’s Key Sources Of Revenue? – Forbes” on February 15, 2019. More interesting news about The Estée Lauder Companies Inc. (NYSE:EL) were released by: Investorplace.com and their article: “5 Consumer Stocks to Cash Out Of – Investorplace.com” published on February 14, 2019 as well as Fool.com‘s news article titled: “3 Ways Investors Can Benefit From Instagram (Hint: Facebook Isn’t One of Them) – Motley Fool” with publication date: February 15, 2019.

Analysts await The Estée Lauder Companies Inc. (NYSE:EL) to report earnings on May, 1. They expect $1.29 earnings per share, up 10.26% or $0.12 from last year’s $1.17 per share. EL’s profit will be $465.90M for 31.55 P/E if the $1.29 EPS becomes a reality. After $1.74 actual earnings per share reported by The Estée Lauder Companies Inc. for the previous quarter, Wall Street now forecasts -25.86% negative EPS growth.

Washington Trust Company increased Marsh & Mclennan Cos Inc (NYSE:MMC) stake by 4,928 shares to 63,551 valued at $5.07 million in 2018Q4. It also upped Ishares/Usa (IWR) stake by 665,201 shares and now owns 893,671 shares. Ishares Etfs/Usa (EFA) was raised too.

More notable recent Amedisys, Inc. (NASDAQ:AMED) news were published by: Seekingalpha.com which released: “Amedisys Q4 2018 Earnings Preview – Seeking Alpha” on February 26, 2019, also Seekingalpha.com with their article: “Amedisys beats by $0.06, beats on revenue – Seeking Alpha” published on February 27, 2019, Globenewswire.com published: “Amedisys to Present at 29th Annual Oppenheimer Healthcare Conference – GlobeNewswire” on March 05, 2019. More interesting news about Amedisys, Inc. (NASDAQ:AMED) were released by: Globenewswire.com and their article: “Amedisys Signs Definitive Agreement to Acquire RoseRock Healthcare – GlobeNewswire” published on February 19, 2019 as well as Nasdaq.com‘s news article titled: “Amedisys Reports Fourth Quarter and Year End 2018 Financial Results Issues 2019 Guidance – Nasdaq” with publication date: February 27, 2019.

Since January 1, 0001, it had 0 insider buys, and 9 sales for $3.76 million activity.

The stock increased 0.67% or $0.83 during the last trading session, reaching $125.45. About 215,640 shares traded. Amedisys, Inc. (AMED) has risen 111.59% since March 15, 2018 and is uptrending. It has outperformed by 107.22% the S&P500. Some Historical AMED News: 20/04/2018 – DJ Amedisys Inc, Inst Holders, 1Q 2018 (AMED); 07/05/2018 – AMEDISYS 1Q REV. $399.3M, EST. $395.5M; 07/05/2018 – Amedisys 1Q EPS 79c; 24/04/2018 – Amedisys Welcomes Sharon Brunecz as Chief Human Resources Officer; 02/05/2018 – Amedisys Closes on Acquisition Expanding Personal Care to Tennessee; 07/05/2018 – AMEDISYS INC QTRLY NET INCOME ATTRIBUTABLE TO AMEDISYS, INC. PER DILUTED SHARE OF $0.79; 07/05/2018 – AMEDISYS REAFFIRMS 2018 GUIDANCE; 07/05/2018 – AMEDISYS 1Q ADJ EPS 79C, EST. 67C; 07/05/2018 – AMEDISYS INC QTRLY NET SERVICE REVENUE INCREASED $34.6 MLN TO $399.3 MLN; 07/05/2018 – AMEDISYS SEES FY NET SERVICE REV. $1.60B TO $1.64B

Sivik Global Healthcare Llc holds 1.26% of its portfolio in Amedisys, Inc. for 20,000 shares. Cypress Capital Management Llc (Wy) owns 5,010 shares or 1.13% of their US portfolio. Moreover, De Burlo Group Inc has 1.01% invested in the company for 38,450 shares. The Massachusetts-based Bogle Investment Management L P De has invested 0.95% in the stock. Cortina Asset Management Llc, a Wisconsin-based fund reported 119,059 shares.

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. The company has market cap of $4.02 billion. It operates through three divisions: Home Health, Hospice, and Personal Care. It has a 35.34 P/E ratio. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Analysts await Amedisys, Inc. (NASDAQ:AMED) to report earnings on May, 6. They expect $0.90 EPS, up 13.92% or $0.11 from last year’s $0.79 per share. AMED’s profit will be $28.81 million for 34.85 P/E if the $0.90 EPS becomes a reality. After $0.91 actual EPS reported by Amedisys, Inc. for the previous quarter, Wall Street now forecasts -1.10% negative EPS growth.

Amedisys, Inc. (NASDAQ:AMED) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.